Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

(2010) G. C. Ebers et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

(2010) RA Bermel et al.   Multiple Sclerosis Journal

High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis

(2009) Hans-Peter Hartung   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison

(2008) Mark S. Freedman et al.   EUROPEAN NEUROLOGY

Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis

(2008) Jennifer Elston Lafata et al.   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION